(Date:12/7/2009)... -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... St. George,s Hospital, University of London during a ... ("ASH") Annual Meeting updated results from the pivotal ... pixantrone (the "PIX 301 EXTEND trial") in relapsed ... who have failed 2 or more prior therapies. ...
(Date:12/6/2009)... ORLEANS and SUNNYVALE, Calif., Dec. 6 ... interim results from a Phase I/II study showing ... / recurrent non-Hodgkin,s Lymphoma (NHL) treated with its ... data were presented today at the 51st ASH ... (Abstract # 2726). ,, PCI-24781 is an ...
(Date:12/6/2009)... of feline DNA in virus , , SUNDAY, Dec. 6 (HealthDay ... might be found in a tiger that lived thousands or ... appears the virus took on a bit of a tiger,s ... remains in the virus to this day. That tiger, in ... of the virus that ultimately led to its infection of ...
(Date:12/6/2009)... Hamilton, ON. Dec. 6, 2009 A new study ... disorder known as venous thromboembolism (VTE). , The ... Americans every year, and occurs when an abnormal clot ... blood, causing pain and swelling. In some cases, the ... travel through the heart to the lungs, causing a ...
(Date:12/5/2009)... ORLEANS, Dec. 5 There have been significant scientific ... experts continue to gain a better understanding of how ... options and provide patients with the best care. Research ... American Society of Hematology explores optimal induction therapies for ...
Breaking Medicine News(10 mins):Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 2Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 3Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 4Health News:Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Follow-Up Data 5Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:AIDS May Date Back to Ancient Tiger 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8... CINCINNATI, Oct. 28 LCA-Vision Inc. (Nasdaq:,LCAV), a ... the,LasikPlus(R) brand, today announced that it will serve ... insurance benefit underwritten by a nationally,known, "A-" (Excellent) ... New York. The benefit provides members covered by,sponsoring ...
... provides "total eSolution" to clinical ... ... ECRFPlus, a software company,focused on developing web-based integrated clinical trials ... with specialty contract research organization (CRO) and ECG core,lab Spacelabs ...
... PROCEDURES, CHICAGO, Oct. 28 While history ... presidential candidates to the person,next door, the economic ... surgery plans. The results of consumer and plastic ... Surgery 2008, the,annual scientific meeting of the American ...
... Woodlands plastic surgery team, Dr. Bob Basu, MD, MPH, FACS and ... and performed the first DIEP free flap breast reconstruction procedure in The ... ... TX (PRWEB) October 28, 2008 -- Dr. Bob Basu and Dr. Sugene ...
... hemoglobin A1c monitoring market is forecast to surpass $272 million by ... population. Other growth drivers include greater glucose control and product innovations ... ... Jose, CA (PRWEB) October 28, 2008 -- World Health Organization forecasts ...
... provider, recently added "Protective Life Insurance Company," to their portfolio ... ... Irvine, CA (PRWEB) October 28, 2008 -- TheHealthQuote continues to ... their current portfolio of top rated insurance companies - which ...
Other Medicine News:Health News:LCA-Vision Named Provider for New Insured Lasik Product 2Health News:LCA-Vision Named Provider for New Insured Lasik Product 3Health News:LCA-Vision Named Provider for New Insured Lasik Product 4Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 2Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 3Health News:ECRFPlus Achieves Milestone Multimillion Dollar Enterprise Agreement With CRO and Launches e-CRF+(TM): a CTMS and EDC Web Platform With ECG Analysis and Cardiac Safety Module. 4Health News:Consumers and Plastic Surgeons Say Economy Is Cutting Into Cosmetic Procedures 2Health News:Consumers and Plastic Surgeons Say Economy Is Cutting Into Cosmetic Procedures 3Health News:Plastic Surgery Team Pioneered the First DIEP Free Flap Breast Reconstruction in The Woodlands, Texas 2Health News:Plastic Surgery Team Pioneered the First DIEP Free Flap Breast Reconstruction in The Woodlands, Texas 3Health News:Plastic Surgery Team Pioneered the First DIEP Free Flap Breast Reconstruction in The Woodlands, Texas 4Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Esteemed Medical and Life Insurance Provider Adds to Their List of Top-Rated Insurance Options 2Health News:Esteemed Medical and Life Insurance Provider Adds to Their List of Top-Rated Insurance Options 3(Date:12/4/2009)... $2.8 million, four-year federal grant will support researchers at ... collaborators at Wake Forest University as they study why ... and how to address the problem. This "storage lesion," ... risk for cardiovascular events and organ failure, particularly among ...
(Date:12/4/2009)... Inc. (VRML) (Pink Sheets: VRMLQ) announced that on December 3, ... related amended Disclosure Statement with the United States Bankruptcy Court ... to consider the adequacy of the Disclosure Statement is presently ... confirmation of the Plan scheduled for January 7, 2010. ,, ...
(Date:12/4/2009)... (OTC Bulletin Board: OXBT) today announced that the first ... dose escalation, clinical trial in Switzerland for use of ... the Company,s perfluorocarbon (PFC) therapeutic oxygen carrier. ,, "This ... of patients with severe TBI. We hope to finally ...
Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2UCI researchers create new strategy for highly selective chemotherapy delivery 58290 1UCI researchers create new strategy for highly selective chemotherapy delivery 58290 2Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 1Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 2Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 3Siebel Foundation awards top UC San Diego bioengineering graduate students 10098 4Nanoparticle based battlefield pain treatment moves a step closer 10094 1Nanoparticle based battlefield pain treatment moves a step closer 10094 2... WIRE)--July 8, 2007 - Cougar Biotechnology,Inc. (OTCBB:CGRB) today ... on the Company's prostate cancer drug candidate CB7630,(abiraterone ... Oncology (ESMO) Conference, which is currently taking place,in ... oral and,poster presentations on Sunday, July 8, as ...
... Positive Phase IIa Clinical,Trial Results, First clinical ... in AM-Pharma's Pipeline , BUNNIK, The Netherlands, ... novel therapeutics to treat,infectious and inflammatory diseases, ... Phase IIa Alkaline Phosphatase (AP) trial,for patients ...
Other Medicine Technology:Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... Para 12 Plus is a hematology control ... 3500/3700. Assay values are provided for the ... a three-part differential on the CELL-DYN 1600 ... and closed-vial stability is 75 days. Para ...
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... 5X is a whole blood hematology control ... 80 and 120, and the Coulter AcT5diff ... a unique white cell differential, positioning the ... on the systems. The product offers 105-day ...
Medicine Products: